Heron Therapeutics(US:HRTX)2025-08-08 12:30Financial Performance - The company generated Q2 2025 net revenue of $37.2 million and year-to-date 2025 net revenue of $76.1 million[9] - Acute Care franchise revenue grew by 55.5% for the three months ended June 30, 2025, compared to the same period last year[9] - The company achieved a record year-to-date 2025 adjusted EBITDA of $7.9 million[9] - Net product sales for Q2 2025 were $37.2 million, compared to $36.024 million in Q2 2024[32] - Adjusted EBITDA for Q2 2025 was $1.771 million, compared to $(1.234) million in Q2 2024[34] Product Performance - ZYNRELEF unit demand grew by 6.3% in Q2 2025 compared to Q1 2025[9] - APONVIE unit demand grew by 19% in Q2 2025 compared to Q1 2025[9] - Acute Care franchise net sales were $10.7 million for the three months ended June 30, 2025[14] - Oncology Care franchise net sales were $26.5 million for the three months ended June 30, 2025[26] Refinancing and Capital Structure - The company completed a comprehensive refinancing of prior debt facilities, reducing total debt from $175 million to $145 million and extending the bullet maturity to 2030+[9] - $110 million was funded at closing from Hercules Capital as a senior secured term loan[38] - $35 million of 50% Senior Convertible Notes were issued to Rubric Capital Management due in 2031[38]